Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cara Therapeutics, Inc. (NASDAQ: CARA).

Full DD Report for CARA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CARA)

A Solution to the Nation's Current Opioid Overdose Epidemic and The World's Leading Cause of Disability
HENDERSON, NV / ACCESSWIRE / December 17, 2018 / Low back pain is the leading cause of disability in the world and the second most cause of disability in the United States. Degenerative disc disease is one of the most common causes of back pain, affecting more than 3 million people in the US...
Source: ACCESSWIRE IA
Date: December, 17 2018 10:20
This Unknown Stock With A Market Opportunity Rivaling Cannabis Could Offer Big Upside For Investors
People who suffer from chronic pain, headaches, and other issues related to the nervous system have new treatments at their fingertips, and two modalities are setting up opportunities for investors with foresight Medical marijuana and its derivatives are gaining rapid acceptance in t...
Source: ACCESSWIRE IA
Date: December, 14 2018 07:30
Cara Therapeutics Inc. (CARA) CEO Derek Chalmers on Q3 2018 Results - Earnings Call Transcript
Cara Therapeutics Inc. (CARA) Q3 2018 Results Earnings Conference Call November 06, 2018, 04:30 PM ET Executives Michael Schaffzin - Stern Investor Relations Derek Chalmers - Co-Founder, President, CEO & Director Mani Mohindru - CFO & Chief Strategy Officer Analysts ...
Source: SeekingAlpha
Date: November, 06 2018 22:47
Cara Therapeutics Q3 cash balance $206M
Cara Therapeutics (NASDAQ: CARA ) Q3 results ($M): Revenue: 5.0. More news on: Cara Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 16:18
Cara Therapeutics misses by $0.01, beats on revenue
Cara Therapeutics (NASDAQ: CARA ): Q3 GAAP EPS of -$0.51 misses by $0.01 . Revenue of $5.06M beats by $0.69M . Press Release More news on: Cara Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:04
Cara Therapeutics Reports Third Quarter 2018 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selec...
Source: GlobeNewswire
Date: November, 06 2018 16:01
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h...
Source: SeekingAlpha
Date: November, 05 2018 13:56
Cannabis and Biotech Stocks That Could Bounce
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / A stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies. They recently reported the findings from Defined Health, which was engaged by BRTX to conduct an independent r...
Source: ACCESSWIRE IA
Date: November, 01 2018 12:20
Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
STAMFORD, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today ann...
Source: GlobeNewswire
Date: October, 30 2018 16:01
Cara Therapeutics: Switch To Calls
Over the past twelve months, the shares of Cara Therapeutics ( CARA ) are up about 45%, and I think now would be a good time for investors to take the money and run. Because this company has many of the characteristics of a lottery ticket, I think it makes much more sense to maintain exposure ...
Source: SeekingAlpha
Date: October, 30 2018 15:26

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1812.4012.3912.4512.15367,636
2018-05-1712.4012.3912.4512.15367,636
2017-02-0316.2216.6516.7515.852,522,041
2017-02-0216.5415.8416.989914.043,951,113
2017-02-0115.6116.4917.2015.35014,734,647

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18188,111417,99445.0033Short
2018-12-17130,944543,58524.0890Cover
2018-12-1451,112206,09124.8007Cover
2018-12-1395,889267,40335.8594Short
2018-12-1238,098128,55629.6353Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CARA.


About Cara Therapeutics, Inc. (NASDAQ: CARA)

Logo for Cara Therapeutics, Inc. (NASDAQ: CARA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CARA)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 15 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 09 2018

       

       


      Daily Technical Chart for (NASDAQ: CARA)

      Daily Technical Chart for (NASDAQ: CARA)


      Stay tuned for daily updates and more on (NASDAQ: CARA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CARA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CARA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CARA and does not buy, sell, or trade any shares of CARA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/